SRNE - ソレント・セラピュ―ティクス (Sorrento Therapeutics Inc.)

SRNEのニュース

   FDA Clearance Means It's Go Time for Sorrento Therapeutics  2020/09/25 18:54:51 InvestorPlace
It's a great time to be long SRNE stock as the company's ambitious Covid-19 treatment clinical trials take a giant step forward.
   Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain  2020/09/22 18:30:00 GlobeNewswire
Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg).No dose limiting toxicities were reported.A majority of patients…
   Sorrento Therapeutics Wins FDA Approval to Proceed With COVID-19 Study  2020/09/17 15:41:00 24/7 Wall street
   Sorrento Surges On FDA Nod For Initiating Clinical Study Of COVID-19 Antibody Treatment  2020/09/17 13:58:00 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares, which are known for being volatile, are headed higher Thursday morning. What Happened: The San Diego, California-based biopharma said the FDA has given its nod for initiating a Phase 1 trial for COVI-GUARD , its stand-alone antibody therapy aimed at blocking viral entry into host cells, in hospitalized COVID-19 patients. COVI-GUARD, aka STI-1499, had previously demonstrated 100% in vitro neutralizing effect against SARS-CoV-2, preventing infection of healthy cells in preclinical studies, the company said. Sorrento also noted that the evaluation of STI-1499 in multiple strains of SARS-CoV-2 in preclinical studies showed the antibody has been 100% effective against even against the … Full story available on Benzinga.com
   Sorrento Therapeutics soars 44% after FDA green-lights COVID-19 antibody trial (SRNE)  2020/09/17 12:58:56 Business Insider
Summary List Placement Sorrento Therapeutics soared on Thursday after the biotechnology firm received clearance from the FDA to proceed with a phase I clinical trial evaluating COVI-GUARD, a COVID-19 antibody test. Sorrento is targeting a potential emergency use authorization submission to the FDA before the end of this year. Sorrento initiated manufacturing processes to produce 50,000 doses in anticipation of receiving emergency use authorization for the COVID-19 antibody. Visit Business Insider's homepage for more stories . Sorrento Therapeutics soared on Thursday after the biotechnology firm received FDA clearance to proceed with a phase I clinical trial evaluating STI-1499, also known as COVI-GUARD, a "neutralizing" antibody for patients who tested positive for COVID-19. Shares traded up as much as 44% to $12 in pre-market trading on Thursday. Sorrento expects a quick enrollment phase for the clinical trial and expects this trial to be followed by large trials targeting a potential emergency use authorization submission to the FDA as early as the end of this year.
   Sorrento Ties The Knot With SmartPharm, Boosting Its Covid-19 Offering  2020/08/21 08:39:31 Smarter Analyst
Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral … The post Sorrento Ties The Knot With SmartPharm, Boosting Its Covid-19 Offering appeared first on Smarter Analyst .
   Covid testing biotech Sorrento stock tumbles 11% after CFO ousted - LearnBonds.com  2020/08/19 14:09:37 LearnBonds
Covid-19 testing firm Sorrento Therapeutics stock plunged more than 11% after it emerged the biotech fired its CFO with immediate effect.
   Sorrento Stock Slumps 13.5% In After-Hours Trading After It Fires CFO  2020/08/19 03:36:00 Benzinga
Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE) traded 13.5% lower in after-hours trading on Tuesday as a reaction to the company firing its Chief …
   Sorrento Therapeutics falls after CFO’s ouster  2020/08/19 01:41:20 Awesome Investors
Jiong Shao is out of the chief financial officer's role at Sorrento Therapeutics (NASDAQ:SRNE), according to a company filing. Shares are down 10.4% after hours. Shao's employment with the company "terminated in its entirety, effectively immediately" yesterday, according to today's filing. Today the company has named Najjam Asghar as its new CFO; he'll take over…
   Sorrento stock falls after company fires CFO  2020/08/18 21:57:30 MarketWatch
Sorrento Therapeutics Inc. undefined shares fell in the extended session Tuesday after the biotech drug maker said it fired its chief financial officer. In a…
   Sorrento Ties The Knot With SmartPharm, Boosting Its Covid-19 Offering  2020/08/21 08:39:31 Smarter Analyst
Sorrento Therapeutics (SRNE) and SmartPharm Therapeutics have now signed a merger agreement for Sorrento to acquire SmartPharm, a gene-encoded therapeutics company developing non-viral … The post Sorrento Ties The Knot With SmartPharm, Boosting Its Covid-19 Offering appeared first on Smarter Analyst .
   Covid testing biotech Sorrento stock tumbles 11% after CFO ousted - LearnBonds.com  2020/08/19 14:09:37 LearnBonds
Covid-19 testing firm Sorrento Therapeutics stock plunged more than 11% after it emerged the biotech fired its CFO with immediate effect.
   Sorrento Stock Slumps 13.5% In After-Hours Trading After It Fires CFO  2020/08/19 03:36:00 Benzinga
Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE) traded 13.5% lower in after-hours trading on Tuesday as a reaction to the company firing its Chief …
   Sorrento Therapeutics falls after CFO’s ouster  2020/08/19 01:41:20 Awesome Investors
Jiong Shao is out of the chief financial officer's role at Sorrento Therapeutics (NASDAQ:SRNE), according to a company filing. Shares are down 10.4% after hours. Shao's employment with the company "terminated in its entirety, effectively immediately" yesterday, according to today's filing. Today the company has named Najjam Asghar as its new CFO; he'll take over…
   Sorrento stock falls after company fires CFO  2020/08/18 21:57:30 MarketWatch
Sorrento Therapeutics Inc. undefined shares fell in the extended session Tuesday after the biotech drug maker said it fired its chief financial officer. In a…

calendar